community Research about RU58841 /Why it was stopped
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
Search
for
Sort by
Community Join
990-1000 / 1000+ resultscommunity 18mo progress - topical fin/min + oral min/dut
The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.
community long term ru58841 users (3 years+), how is it going for you?
Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.
community Topical Dutasteride Experiment
community Here's why Pryiltamide "failed" phase 3 trials and marketed as a cosmetic
KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.
community Burning sensation and acne along temples accompanied by aggressive recession. On 0.5mg dut, 1.25mg fin EOD, and oral min 5mg daily.
The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.
community pyrilutamide any results so far?
The hair loss treatment Pyrilutamide and whether it has had any results for users. Martinsahara is planning to buy some soon.
community how do RU and topical spironolactone compare?
Hair loss treatments RU and topical spironolactone were compared. No specific results or conclusions were provided.
community Where are GT20029 phase II results?
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
community Comparing the effect of T suppression and DHT suppression
The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.